United TherapeuticsUTHR -0.98%88 Return-on-Tangible-Asset is 15.31% as of Mar. 2026, which is 2% below its 10-year median of 15.70. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $387.04 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,009 Drug Manufacturers companies, United Therapeutics ranks better than 92.07% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. United Therapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was $1,100 Mil. United Therapeutics's average total tangible assets for the quarter that ended in Mar. 2026 was $7,181 Mil. Therefore, United Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 15.31%.
The historical rank and industry rank for United Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
UTHR'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2.99 Med: 15.7 Max: 32.09
Current: 17.39
During the past 13 years, United Therapeutics's highest Return-on-Tangible-Asset was 32.09%. The lowest was -2.99%. And the median was 15.70%.
UTHR's Return-on-Tangible-Asset is ranked better than 92.07% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs UTHR: 17.39
United Therapeutics (NAS:UTHR) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
United Therapeutics Return-on-Tangible-Asset Related Terms
United Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics Return-on-Tangible-Asset Chart
UTHR vs VTRS, NBIX, ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 15.31% mean?
United Therapeutics (UTHR) has a Return-on-Tangible-Asset of 15.31% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on United Therapeutics and its competitors. This is near median its historical median of 15.70. According to the industry distribution chart, United Therapeutics ranks #80 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 7.9%.
Is United Therapeutics' Return-on-Tangible-Asset too high?
United Therapeutics' current Return-on-Tangible-Asset of 15.31% is near median its 10-year median of 15.70. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. United Therapeutics' value of 15.31% is 384.5% above this industry median. Based on the distribution chart, United Therapeutics ranks #80 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Return-on-Tangible-Asset compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #80 out of 1009 companies for Return-on-Tangible-Asset. This places United Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. United Therapeutics' value of 15.31% is 384.5% above this benchmark. While the company's 10-year median is 15.70 vs. the industry median of 3.16, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current Return-on-Tangible-Asset of 15.31% is 384.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current Return-on-Tangible-Asset is 15.31%, which is near median its own 10-year median of 15.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $387.04, compared to a current price of $547.06 — trading 41.3% above its estimated fair value. The current Return-on-Tangible-Asset is 15.31%, which is near median its 10-year median of 15.70 and 384.5% above the Drug Manufacturers industry median of 3.16. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Return-on-Tangible-Asset is 15.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $547.06 is trading 41.3% above its estimated GF Value™ of $387.04.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
Return-on-Tangible-Asset: 15.31% (near median its 10-year median of 15.70)
GF Value™: $387.04 vs. price of $547.06 (41.3% above fair value)
Industry Position: 384.5% above the Drug Manufacturers median (#80 of 1009)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
